-
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date
Monday, May 22, 2017 - 12:25pm | 600Read More...Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...
-
Competition For Mylan's Generic Concerta Is Limited
Friday, December 30, 2016 - 9:13am | 249Read More...With Mylan NV (NASDAQ: MYL) announcing the launch of generic Concerta earlier than expected in the United States, BTIG’s Timothy Chiang expressed optimism regarding the stock, stating that the company was likely to benefit from this launch. Chiang maintained a Buy rating on the company,...
-
The FDA's Authority Challenged By Mallinckrodt
Friday, May 15, 2015 - 3:07pm | 471Read More...The American healthcare system became much more affordable with the advent of generic drugs. Many popular medications have lower-costing, alternative treatments that contain the same active ingredients as their costly brand-name rivals, which has saved the public millions in pharmaceutical costs....
-
Watson Pharmaceuticals Earnings Preview
Monday, July 25, 2011 - 11:13am | 647Read More...Watson Pharmaceuticals (NYSE: WPI) is scheduled to report its second-quarter 2011 results Tuesday, July 26, before the markets open. Strong first-quarter results pushed the share price to a new all-time high; can second-quarter results do the same? Analysts are looking for the drug maker to report...
